ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

The Once a Week Anti-Diabetic Drug Has Been Approved For Type II Diabetes Treatment by FDA

Updated on December 14, 2017
Aron Mejias MD profile image

I expect a better-educated society will create a better world. Only when we decrease our beliefs, we can be free.

Source

Novo Nordisk Semaglutide – The Once a Week Anti-Diabetic Drug Has Been Approved For Type II Diabetes Treatment by FDA

The new endorsement by the US Food and Drug Administration (FDA) to Novo Nordisk’s Semaglutide as once a week treatment for type 2 diabetes control was granted on October the 18th after the FDA advisory panel formed by 17 endocrinologist and Metabolic Drugs experts voted 16 in favor of its approval with one abstention.

After considering all the data and clinical trials conducted by the pharmaceutical company on more than 8000 adult patients with type II diabetes, including a two years long study of 3297 patient trials taking the drug for cardiovascular side effects. The FDA advisory panel found enough supporting evidence of the Semaglutide blood sugar lowering effect and its safety. The blood sugar lowering effect was measured by the record of the patients HbA1c or glycosylated hemoglobin, which is the gold-standard test for long-term sugar blood level measurement.

The HbA1c levels were 1.5 to 1.8% lower among the patients’ group receiving the drug compared with the others groups, who were either receiving a placebo or one of the competitors approved drugs. The 1.5 to 1.8% lower HbA1c on the patients treated with Novo Semaglutide was present even when compared with patients treated with Bydureon (exenatide) the AstraZeneca competing long-acting GLP-1 agonist extended release. Additionally, to the proven blood sugar lowering effect Semaglutide was directed associated with another beneficial effect on one clinical trial, the patient studied showed a 4.5- to 6.4-kg weight loss.

Source

What is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor, agonist. It imitates the normal hormone secreted by the intestinal cells called Glucagon, which produces to increase insulin secretion by the pancreas’ cells in the presence of elevated blood glucose; delays gastric emptying, which decreases the blood sugar after food or meals ingestion; also, the glucagon-like peptide 1 reduces the physiological glucagon secretion.

Concisely, Semaglutide mechanism of action is similar to the naturally secreted body hormone glucagon. The drug acts on the same receptor for the hormone and produces similar response reducing the blood sugar level.

How is Semaglutide prescribed and it is safe for your heart?

How is Semaglutide prescribed?

Semaglutide prescription is one per week subcutaneous injection of 0.5 or 1 mg an adjunct to diet and exercise to get or improve blood sugar control in adults with type 2 Diabetes

Semaglutide is safe for your heart

After several studies, there was not found any side effect for heart, arteries, or veins in patients receiving the Semaglutide during the two years clinical observation period. On the contrary, Semaglutide SUSTAIN-6 Top-line Data shows a cut on cardiovascular risk among those receiving it. Therefore, the FDA considered it cardiovascular safe, and with some protective or beneficial effects, additional observation and studies will continue as part of its post-marketing surveillance.

Semaglutide diabetic retinopathy controversy

The clinical trials showed an increased report of retinopathy cases among the patients receiving Semaglutide. After a careful revision of the data from those tests, the retinopathy was found as a confounding element. The revision panel found that the patient had developed the retinopathy before they were receiving the Semaglutide, and the condition might or might not be worsening by the drug. However, the FDA demands that a safety warning must be included on the drug label indicating the risk of developing or worsening retinopathy.

The ophthalmologist members of the revision commission agreed about the primary outcomes of safety concern were met. They said that the side effects were the same as expected for similar drugs and not worrisome. The data were insufficient to determine if there is an adverse retinopathy effect o not associated with the Semaglutide treatment.

Consequently, further studies and epidemiologic vigilance are needed to establish any possible association. Other ophthalmologist consulted about it indicated that having a warning on the label about periodical eye exam on the patient receiving the drug was not only a good idea but also the best possible recommendation for the patients’ best interest.

Source

The approval for patient use of the Semaglutide is welcome by the medical community and the patient with type II diabetes. Type II diabetes patients can have a drug that works helping them reducing their blood sugar level with only one single weekly injection or a single dose per week. The single dose makes it easier to comply with the medical treatment. It proved to work and lowered the blood sugar levels when used simultaneously with diet and exercise. The additional weight loss effect improves further the blood sugar level control.

Type II diabetes patients require a yearly eye examination to discard diabetic retinopathy as the standard of care. Patient receiving semaglutide needs to be warned about a possible development or worsening of diabetic retinopathy and maintain the yearly or more frequent eye examination if they already had developed a retinopathy.

Comments

    0 of 8192 characters used
    Post Comment

    No comments yet.

    working

    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, hubpages.com uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at: https://hubpages.com/privacy-policy#gdpr

    Show Details
    Necessary
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the googleapis.com or gstatic.com domains, for performance and efficiency reasons. (Privacy Policy)
    Features
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Marketing
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Statistics
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)